Table 1.
Baseline Characteristics
| Parameters | Value |
|---|---|
| Age (years) | 55.62±9.24 |
| Gender (n/%) | |
| Male | 25(83.33%) |
| Female | 5(16.67%) |
| Cirrhosis (n/%) | |
| Y | 27(90.00%) |
| N | 3(10.00%) |
| ECOG performance status | |
| 0–1 | 20(66.67%) |
| 2 | 10(33.33%) |
| Child-Pugh stage (n/%) | |
| A | 21(70.00%) |
| B | 9(30.00%) |
| Prior c-TACE number(n/%) | |
| 2 | 6(20.00%) |
| >2 | 24(80.00%) |
| AFP | 27,557.62±18,991.47 |
| TBiL(umol/L) | 25.72±19.34 |
| ALB(g/L) | 38.48±22.78 |
| Tumor number(n/%) | |
| ≤3 | 24(80.00%) |
| >3 | 6(20.00%) |
| Maximum tumor diameter | 6.78±3.18 |
| PVTT(n/%) | |
| Y | 3(10.00%) |
| N | 27(90.00%) |
| Extrahepatic spread(n/%) | |
| Y | 5(16.67%) |
| N | 25(83.33%) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; c-TACE, conventional transcatheter arterial chemoembolization; AFP, alpha fetoprotein; TBiL, total bilirubin; ALB, albumin; PVTT, portal vein tumor thrombus.